Aurobindo Pharma says Rs 420 crore deal to acquire 51 per cent in Cronus Pharma cancelled

On August 12, the company had announced that it had entered into definitive agreements to subscribe to fresh equity shares in Hyderabad-based Cronus, a generic veterinary pharmaceutical products firm engaged in development, manufacturing and sale of these items.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news